Nhlbi
Nhlbi funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.
NIH RFA-HL-26-018: CATALYZE Product Definition for Small-Molecule Biologic Combination Therapies
A National Heart, Lung, and Blood Institute RFA to fund short-cycle R33 projects that de-risk combination therapy platforms by producing a clear translational product plan from preclinical or early clinical work.
PAR-24-211: NHLBI Career Transition Award (K22 Clinical Trial Required)
NIH Career Development K22 program for intramural NHLBI postdocs and research trainees transitioning to independent extramural investigators, with two required review/training phases and a full-project duration of up to five years.
PAR-27-013: Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (U24)
The NHLBI PAR-27-013 funding opportunity supports Data Coordinating Center (DCC) teams that coordinate multi-site investigator-initiated clinical trials in a milestone-driven cooperative agreement, submitted alongside a companion Clinical Coordinating Center application.
RFA-HL-26-003: NHLBI Emerging Investigator Award (EIA) (R35, Clinical Trial Optional)
NIH’s NHLBI Emerging Investigator Award (R35, clinical trial optional) supports established HLBS investigators with at least two NHLBI R01-equivalent grants for up to seven years of flexible, program-level funding, with the next listed due date on 19 February 2027.
RFA-HL-26-016: Catalyze Enabling Technologies and Transformative Platforms for HLBS Research (R33)
NIH's NHLBI Catalyze R33 opportunity funds enabling technologies and transformative platforms in heart, lung, blood, and sleep (HLBS) research with strong validation milestones and measurable performance measures.
RFA-HL-26-019: Catalyze Product Definition - Medical Device Prototype Design/Testing, Diagnostics, and Assay Development (R61/R33)
NIH NHLBI Catalyze Product Definition NOFO for phased R61/R33 support of early-stage device, diagnostic, and assay development (clinical trials not allowed), with ongoing application rounds in 2026 and 2027.
RFA-HL-27-004: Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)
NIH’s NHLBI RFA-HL-27-004 is a limited-competition R03 small grant opportunity to help current and recently completed NHLBI K01/K08/K23/K25 awardees advance toward independent funding through a short, NIH-funded pilot- to proof-of-concept scale project.